Takeda Culls Shunned Ex-Shire Asset After EC Lifts Antimonopoly Concerns
But Data, Samples Made Available
Executive Summary
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.